Document resource
Introduction Cirrhotic Alcohol-Associated Liver Disease (cArLD) imposes a significant global health and socioeconomic burden due to the associated morbidity, diminished quality of life, and mortality. Therefore, evaluating the temporal trends in the incidence and disease burden of cArLD is of paramount importance as it enables risk stratification and implementation of policy measures.Methods Temporal trends in the incidence and burden of cArLD in the United Kingdom (UK) were evaluated by retrieving data from the Global Burden of Disease database consisting of the age-standardised incidence rate (ASIR) and age-standardised Disability-Adjusted Life Year (DALY) rate (ASDR) of cArLD in the UK for the period of 1990-2023. Joinpoint regression analysis was performed to calculate the Annual Percent Change (APC) and the Average Annual Percent Change (AAPC). To evaluate for potential national and region differences, data was sub-analysed into the four nations of the UK; England, Wales, Scotland, and Northern Ireland along with the various regions within England.Results Over a span of 33 years, an estimated total of 165,415 cArLD cases with a male predominance of 70.5% were reported across the UK. England accounted for the majority of cases, 82.5%, followed by Scotland which accounted for 7.7% of the cases. A statistically significant increase in cArLD ASIR was observed across the UK with an AAPC of 1.15 (95%CI 1.08 to 1.19, p<0.001). Across the four nations, a statistically significant increase in the ASIR was observed with the highest increase noted in Northern Ireland (AAPC 2.29, 95%CI 2.27 to 2.32, p<0.001), followed by Wales (AAPC 1.86, 95%CI 1.84 to 1.88, p<0.001), England (AAPC 1.13, 95%CI 1.05 to 1.18, p<0.001), and Scotland (AAPC 0.70, 95%CI 0.68 to 0.72, p<0.001). Across England, a statistically significant increase in cArLD ASIR was noted across the regions with the highest incline being observed in North East England (AAPC 1.60, 95%CI 1.51 to 1.67, p<0.001) whereas the lowest incline was noted in Greater London (AAPC 0.18, 95%CI 0.13 to 0.21, p<0.001).In regard to disease burden, a statistically significant increase in cArLD ASDR was witnessed in the UK with an AAPC of 2.17 (95%CI 2.08 to 2.30, p<0.001). Similarly, a statistically significant increase in the ASDR was observed across the four nations with the highest increase being in Northern Ireland (AAPC 3.65, 95%CI 3.24 to 4.04, p<0.001), followed by Wales (AAPC 2.87, 95%CI 2.69 to 3.09, p<0.001), England (AAPC 2.24, 95%CI 2.14 to 2.37, p<0.001), and Scotland (AAPC 1.07, 95%CI 0.95 to 1.25, p<0.001).Conclusions Over the period 1190-2023, The UK has experienced a worrisome increase in the incidence and disease-related burden of cArLD that warrants prompt recognition and action.